Seqirus Vaccines Limited, headquartered in Great Britain, is a leading player in the global vaccine industry, specialising in the development and production of innovative vaccines. Founded in 2015, Seqirus emerged from the merger of bioCSL and Novartis Vaccines, quickly establishing itself as a key provider of seasonal influenza vaccines and other critical immunisation solutions. With a strong operational presence across Europe, North America, and Asia-Pacific, Seqirus is dedicated to addressing public health needs through its advanced vaccine technologies. The company’s core products include a range of flu vaccines, which are distinguished by their high efficacy and safety profiles. Notably, Seqirus has achieved significant milestones, including the development of the first adjuvanted flu vaccine for older adults, reinforcing its commitment to innovation and excellence in vaccine delivery.
We don't have data for Seqirus Vaccines Limited, but we can show you information about their parent organization instead.
View parent company